Metrion Biosciences, a specialist preclinical CRO, has appointed Dr Chris Mathes as its Chief Commercial Officer (CCO).
Chris will work with the company’s leadership team to drive commercial strategy, as well as global business development and marketing activities.
Chris’ appointment as CCO further strengthens Metrion’s senior management team, boosting its scientific and commercial capabilities and driving the company’s expansion in key global markets.
Mathes has more than 25 years experience in the biopharmaceutical industry, specialising in the preclinical CRO space, where he has developed many high-performance sales and marketing strategies.
He has held executive-level positions at Sophion Bioscience, ChanTest AnaBios and Icagen.
Prior to his appointment as CCO, Chris has been a business advisor to Metrion for its US division.
CEO of Metrion Biosciences, Andrew Southan said: “Chris brings outstanding commercial and scientific expertise to Metrion’s senior management team. His experience in leading ion channel and preclinical drug discovery commercial operations globally is second to none. Chris adds depth to our neuroscience expertise, further strengthens our presence in the USA, and I am confident he will make a substantial contribution towards achieving Metrion’s vision of becoming the leading preclinical ion channel service provider.”
